MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
PharmaDrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands, Initiates Major Push to Acquire Best of Breed High Traffic Locations
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
Psychedelics Stock Warrants Offer Interesting Leverage Play
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs
Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.
Numinus Announces Listing of Warrants
Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
MindMed Inc has applied to up-list on the NASDAQ.
Mind Cure Targets Multi-Billion Dollar Sweet-Spot in Life Sciences
The road to psychedelic drug success leads through functional mushrooms.
Why Canada Is The Natural Launch-Pad For The Psychedelic Drug Industry
Canada stands out as the premier destination for psychedelic drug companies.
Compass’s Upsized IPO Financing Sends ‘Buy’ Signal For Sector
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering
Newest IPO hits September 21- MCUR
COMPASS Pathways announces pricing of upsized initial public offering
Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).
